The 2020 American College of Rheumatology Reproductive Health Management Guidelines for Rheumatoid and Musculoskeletal Diseases recommend HCQ treatment for all pregnant women positive for anti-SSA/Ro-and/or anti-SSB/La antibodies to reduce CHB risk [89]. The gene discussed is RO60; the disease is musculoskeletal system disorder.